Lipoxin analogs: novel anti-inflammatory mediators.
Most pharmacological anti-inflammatory agents are designed to inhibit the enzymes or receptors that are directly involved in mediating inflammation. In contrast, lipoxin analogs utilize an entirely different anti-inflammatory paradigm, namely that of activating the endogenous anti-inflammatory signaling pathways by which inflammation is normally resolved. Specifically, synthetic stable analogs of the endogenous anti-inflammatory eicosanoid lipoxin A4 (LXA4) have been shown to mimic the anti-inflammatory actions of LXA4 in a variety of inflammation models and display desirable pharmacological properties, especially their high oral bioavailability. Lipoxin analogs could be potentially useful for a wide array of disease states that have an inflammatory component, and look particularly promising for treatment of inflammatory bowel disease.
Gewirtz
Andrew
A
Pathology-WBRB 105H, Emory University, 615 Michael Street, Atlanta, GA 30322, USA. agewirt@emory.edu
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002478:Cells, Cultured; D004195:Disease Models, Animal; D015195:Drug Design; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D044045:Lipoxins / Q000494:pharmacology* / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
D000893:Anti-Inflammatory Agents; D044045:Lipoxins